Federal Judge Declines Bayer Injunction Seeking to Halt Johnson & Johnson Claims on Prostate Cancer Drug
A U.S. district judge in Manhattan refused Bayer's request for an injunction that would have stopped Johnson & Johnson from promoting claims that its prostate cancer drug Erleada cuts the risk of death by roughly half compared with Nubeqa. The court concluded Bayer had not demonstrated it was likely to prevail on the merits of its false advertising…